Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Authors: Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda Duska, Marta A. Crispens, Alexander Olawaiye, Ira Winer, Lisa Barroilhet, Siqing Fu, Michael McHale, Russell J. Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne Quinn, Brittany Bowes, Alan D. D’Andrea, Geoffrey I. Shapiro, Ursula A. Matulonis - The Lancet 2020 cited by 232